Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Benedetta Conte"'
Autor:
Benedetta Conte, Fara Brasó-Maristany, Adela Rodríguez Hernández, Tomás Pascual, Guillermo Villacampa, Francesco Schettini, Maria J. Vidal Losada, Elia Seguí, Laura Angelats, Isabel Garcia-Fructuoso, Raquel Gómez-Bravo, Natàlia Lorman-Carbó, Laia Paré, Mercedes Marín-Aguilera, Olga Martínez-Sáez, Barbara Adamo, Esther Sanfeliu, Beatrice Fratini, Claudette Falato, Núria Chic, Ana Vivancos, Patricia Villagrasa, Johan Staaf, Joel S. Parker, Charles M. Perou, Aleix Prat
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105043- (2024)
Summary: Background: Early-stage triple-negative breast cancer (TNBC) displays clinical and biological diversity. From a biological standpoint, immune infiltration plays a crucial role in TNBC prognosis. Currently, there is a lack of genomic tools ai
Externí odkaz:
https://doaj.org/article/e280cec22ed2498189d321ebd159a946
Autor:
Francesco Schettini, Elia Seguí, Benedetta Conte, Esther Sanfeliu, Blanca Gonzalez-Farre, Pedro Jares, Sergi Vidal-Sicart, Sergi Ganau, Isaac Cebrecos, Fara Brasó-Maristany, Montserrat Muñoz, Aleix Prat, Maria Vidal
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundCDK4/6 inhibitors (CDKi), namely, palbociclib, ribociclib, and abemaciclib, combined with either an aromatase inhibitor (AI) or fulvestrant are the standard first/second line for hormone receptor-positive(HR+)/HER2-negative(neg) metastatic
Externí odkaz:
https://doaj.org/article/4c555861a9c24c34a6e369dd882b1e25
Autor:
Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/b28722479f184275ad15e398ece44187
Autor:
Olga Martínez-Sáez, Tomás Pascual, Fara Brasó-Maristany, Nuria Chic, Blanca González-Farré, Esther Sanfeliu, Adela Rodríguez, Débora Martínez, Patricia Galván, Anna Belén Rodríguez, Francesco Schettini, Benedetta Conte, Maria Vidal, Barbara Adamo, Antoni Martínez, Montserrat Muñoz, Reinaldo Moreno, Patricia Villagrasa, Fernando Salvador, Eva M. Ciruelos, Iris Faull, Justin I. Odegaard, Aleix Prat
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract Circulating tumor DNA (ctDNA) levels may predict response to anticancer drugs, including CDK4/6 inhibitors and endocrine therapy combinations (CDK4/6i+ET); however, critical questions remain unanswered such as which assay or statistical meth
Externí odkaz:
https://doaj.org/article/9539a7ac44b6431f941c92563bf19fa9
Autor:
Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-13 (2021)
Abstract Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC
Externí odkaz:
https://doaj.org/article/2eba3978bf5741538c429b49f4a590be
Autor:
Aleix Prat, Valentina Guarneri, Tomás Pascual, Fara Brasó-Maristany, Esther Sanfeliu, Laia Paré, Francesco Schettini, Débora Martínez, Pedro Jares, Gaia Griguolo, Maria Vittoria Dieci, Javier Cortés, Antonio Llombart-Cussac, Benedetta Conte, Mercedes Marín-Aguilera, Nuria Chic, Joan Anton Puig-Butillé, Antonio Martínez, Patricia Galván, Yi-Hsuan Tsai, Blanca González-Farré, Aurea Mira, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, Pierfranco Conte, Charles M. Perou
Publikováno v:
EBioMedicine, Vol 75, Iss , Pp 103801- (2022)
Summary: Background: Both clinical and genomic data independently predict survival and treatment response in early-stage HER2-positive breast cancer. Here we present the development and validation of a new HER2DX risk score, and a new HER2DX patholog
Externí odkaz:
https://doaj.org/article/0fd537b853eb4d46994417b689144024
Autor:
Olga Martínez-Sáez, Nuria Chic, Tomás Pascual, Barbara Adamo, Maria Vidal, Blanca González-Farré, Esther Sanfeliu, Francesco Schettini, Benedetta Conte, Fara Brasó-Maristany, Adela Rodríguez, Débora Martínez, Patricia Galván, Ana Belén Rodríguez, Antonio Martinez, Montserrat Muñoz, Aleix Prat
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-9 (2020)
Abstract Purpose The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknow
Externí odkaz:
https://doaj.org/article/82966bc1ef824877920c73977a48ab41
Autor:
Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos Pusztai, Mothaffar F. Rimawi, Rachel Schiff, Grazia Arpino, Sabino De Placido, Aleix Prat, Daniele Generali
Publikováno v:
Cancers, Vol 13, Iss 6, p 1458 (2021)
A precise assessment of the efficacy of first-/second-line endocrine therapies (ET) ± target therapies (TT) in clinically-relevant subgroups of hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (MBC) has not yet been conducted.
Externí odkaz:
https://doaj.org/article/6e71f2978c4246208d66c9afdb5ac240
Autor:
Francesca Poggio, Matteo Lambertini, Claudia Bighin, Benedetta Conte, Eva Blondeaux, Alessia D’Alonzo, Chiara Dellepiane, Giulia Buzzatti, Chiara Molinelli, Francesco Boccardo, Lucia Del Mastro
Publikováno v:
Clinical Medicine Insights: Reproductive Health, Vol 13 (2019)
The use of chemotherapy in premenopausal cancer patients may lead to chemotherapy-induced premature ovarian failure. Pharmacological temporary ovarian suppression obtained with the gonadotropin-releasing hormone agonist (GnRHa) administered concomita
Externí odkaz:
https://doaj.org/article/7b08a45699454f6a8787d165672deeaa
Autor:
Francesca Poggio, Marco Tagliamento, Chiara Pirrone, Davide Soldato, Benedetta Conte, Chiara Molinelli, Maurizio Cosso, Piero Fregatti, Lucia Del Mastro, Matteo Lambertini
Publikováno v:
Cancers, Vol 12, Iss 12, p 3616 (2020)
The diagnosis of breast cancer during pregnancy represents a challenging situation for the patient, her caregivers and physicians. Pregnancy adds complexity to oncological treatment planning, as many therapies can be potentially dangerous to the fetu
Externí odkaz:
https://doaj.org/article/5794ae47d7d04be587fa21d562cc217e